Ceramide kinase mediates intrinsic resistance and inferior response to chemotherapy in triple‐negative breast cancer by upregulating Ras/ERK and PI3K/Akt pathways
Abstract Background Clinical management of triple-negative breast cancer (TNBC) patients remain challenging because of the development of chemo-resistance. Identification of biomarkers for risk stratification of chemo-resistance and therapeutic decision-making to overcome such resistance is thus nec...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | Cancer Cell International |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12935-020-01735-5 |
id |
doaj-5cec94fa3f5140cc8ef8e5bf5a31d40b |
---|---|
record_format |
Article |
spelling |
doaj-5cec94fa3f5140cc8ef8e5bf5a31d40b2021-01-17T12:20:59ZengBMCCancer Cell International1475-28672021-01-0121111110.1186/s12935-020-01735-5Ceramide kinase mediates intrinsic resistance and inferior response to chemotherapy in triple‐negative breast cancer by upregulating Ras/ERK and PI3K/Akt pathwaysShan Zhu0Yulin Xu1Lijun Wang2Shichong Liao3Yuan Wang4Manman Shi5Yi Tu6Yurong Zhou7Wen Wei8Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan UniversityDepartment of Breast and Thyroid Surgery, Renmin Hospital of Wuhan UniversityDepartment of Breast and Thyroid Surgery, Renmin Hospital of Wuhan UniversityDepartment of Breast and Thyroid Surgery, Renmin Hospital of Wuhan UniversityDepartment of Breast and Thyroid Surgery, Renmin Hospital of Wuhan UniversityDepartment of Breast and Thyroid Surgery, Renmin Hospital of Wuhan UniversityDepartment of Breast and Thyroid Surgery, Renmin Hospital of Wuhan UniversityDepartment of Radiology, Zhongnan Hospital of Wuhan UniversityDepartment of Breast and Thyroid Surgery, Renmin Hospital of Wuhan UniversityAbstract Background Clinical management of triple-negative breast cancer (TNBC) patients remain challenging because of the development of chemo-resistance. Identification of biomarkers for risk stratification of chemo-resistance and therapeutic decision-making to overcome such resistance is thus necessary. Methods Retrospective analysis was performed to identify potential stratification biomarkers. The levels of ceramide kinase (CERK) was determined in breast cancer patients. The roles of CERK and its downstream signaling pathways were analysed using cellular and biochemical assays. Results CERK upregulation was identified as a biomarker for chemotherapeutic response in TNBC. A > 2-fold change in CERK (from tumor)/CERK (from normal counterpart) was significantly associated with chemo-resistance (OR = 2.66, 95% CI 1.18–7.34), P = 0.04. CERK overexpression was sufficient to promote TNBC growth and migration, and confer chemo-resistance in TNBC cell lines, although this resistance could be overcome via CERK inhibition. Mechanistic studies suggest that CERK mediates intrinsic resistance and inferior response to chemotherapy in TNBC by regulating multiple oncogenic pathways such as Ras/ERK, PI3K/Akt/mTOR, and RhoA. Conclusions Our work provides an explanation for the heterogeneity of chemo-response across TNBC patients and demonstrates that CERK inhibition offers a therapeutic strategy to overcome treatment resistance.https://doi.org/10.1186/s12935-020-01735-5CERKCP-1TNBCChemoresistanceRasBiomarker |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shan Zhu Yulin Xu Lijun Wang Shichong Liao Yuan Wang Manman Shi Yi Tu Yurong Zhou Wen Wei |
spellingShingle |
Shan Zhu Yulin Xu Lijun Wang Shichong Liao Yuan Wang Manman Shi Yi Tu Yurong Zhou Wen Wei Ceramide kinase mediates intrinsic resistance and inferior response to chemotherapy in triple‐negative breast cancer by upregulating Ras/ERK and PI3K/Akt pathways Cancer Cell International CERK CP-1 TNBC Chemoresistance Ras Biomarker |
author_facet |
Shan Zhu Yulin Xu Lijun Wang Shichong Liao Yuan Wang Manman Shi Yi Tu Yurong Zhou Wen Wei |
author_sort |
Shan Zhu |
title |
Ceramide kinase mediates intrinsic resistance and inferior response to chemotherapy in triple‐negative breast cancer by upregulating Ras/ERK and PI3K/Akt pathways |
title_short |
Ceramide kinase mediates intrinsic resistance and inferior response to chemotherapy in triple‐negative breast cancer by upregulating Ras/ERK and PI3K/Akt pathways |
title_full |
Ceramide kinase mediates intrinsic resistance and inferior response to chemotherapy in triple‐negative breast cancer by upregulating Ras/ERK and PI3K/Akt pathways |
title_fullStr |
Ceramide kinase mediates intrinsic resistance and inferior response to chemotherapy in triple‐negative breast cancer by upregulating Ras/ERK and PI3K/Akt pathways |
title_full_unstemmed |
Ceramide kinase mediates intrinsic resistance and inferior response to chemotherapy in triple‐negative breast cancer by upregulating Ras/ERK and PI3K/Akt pathways |
title_sort |
ceramide kinase mediates intrinsic resistance and inferior response to chemotherapy in triple‐negative breast cancer by upregulating ras/erk and pi3k/akt pathways |
publisher |
BMC |
series |
Cancer Cell International |
issn |
1475-2867 |
publishDate |
2021-01-01 |
description |
Abstract Background Clinical management of triple-negative breast cancer (TNBC) patients remain challenging because of the development of chemo-resistance. Identification of biomarkers for risk stratification of chemo-resistance and therapeutic decision-making to overcome such resistance is thus necessary. Methods Retrospective analysis was performed to identify potential stratification biomarkers. The levels of ceramide kinase (CERK) was determined in breast cancer patients. The roles of CERK and its downstream signaling pathways were analysed using cellular and biochemical assays. Results CERK upregulation was identified as a biomarker for chemotherapeutic response in TNBC. A > 2-fold change in CERK (from tumor)/CERK (from normal counterpart) was significantly associated with chemo-resistance (OR = 2.66, 95% CI 1.18–7.34), P = 0.04. CERK overexpression was sufficient to promote TNBC growth and migration, and confer chemo-resistance in TNBC cell lines, although this resistance could be overcome via CERK inhibition. Mechanistic studies suggest that CERK mediates intrinsic resistance and inferior response to chemotherapy in TNBC by regulating multiple oncogenic pathways such as Ras/ERK, PI3K/Akt/mTOR, and RhoA. Conclusions Our work provides an explanation for the heterogeneity of chemo-response across TNBC patients and demonstrates that CERK inhibition offers a therapeutic strategy to overcome treatment resistance. |
topic |
CERK CP-1 TNBC Chemoresistance Ras Biomarker |
url |
https://doi.org/10.1186/s12935-020-01735-5 |
work_keys_str_mv |
AT shanzhu ceramidekinasemediatesintrinsicresistanceandinferiorresponsetochemotherapyintriplenegativebreastcancerbyupregulatingraserkandpi3kaktpathways AT yulinxu ceramidekinasemediatesintrinsicresistanceandinferiorresponsetochemotherapyintriplenegativebreastcancerbyupregulatingraserkandpi3kaktpathways AT lijunwang ceramidekinasemediatesintrinsicresistanceandinferiorresponsetochemotherapyintriplenegativebreastcancerbyupregulatingraserkandpi3kaktpathways AT shichongliao ceramidekinasemediatesintrinsicresistanceandinferiorresponsetochemotherapyintriplenegativebreastcancerbyupregulatingraserkandpi3kaktpathways AT yuanwang ceramidekinasemediatesintrinsicresistanceandinferiorresponsetochemotherapyintriplenegativebreastcancerbyupregulatingraserkandpi3kaktpathways AT manmanshi ceramidekinasemediatesintrinsicresistanceandinferiorresponsetochemotherapyintriplenegativebreastcancerbyupregulatingraserkandpi3kaktpathways AT yitu ceramidekinasemediatesintrinsicresistanceandinferiorresponsetochemotherapyintriplenegativebreastcancerbyupregulatingraserkandpi3kaktpathways AT yurongzhou ceramidekinasemediatesintrinsicresistanceandinferiorresponsetochemotherapyintriplenegativebreastcancerbyupregulatingraserkandpi3kaktpathways AT wenwei ceramidekinasemediatesintrinsicresistanceandinferiorresponsetochemotherapyintriplenegativebreastcancerbyupregulatingraserkandpi3kaktpathways |
_version_ |
1724334995931136000 |